GHRH analogue research in Canada encompasses a family of synthetic peptides that mimic the action of endogenous growth hormone-releasing hormone to stimulate pituitary GH secretion. Endogenous GHRH is a 44-amino acid hypothalamic neuropeptide, and multiple synthetic analogues have been developed with improved stability and pharmacokinetics. Canadian growth hormone axis researchers study GHRH analogues — primarily sermorelin (GHRH 1-29), CJC-1295 (with and without DAC), and tesamorelin (trans-3-hexenoic-GHRH) — to understand pituitary somatotroph biology and GH secretion dynamics.
Sermorelin: Short-Acting GHRH Research Tool
Sermorelin corresponds to the first 29 N-terminal amino acids of GHRH, representing the minimal active sequence for GHRH receptor binding. Its short half-life (~10-20 minutes) makes it useful for studying pulsatile GHRH receptor activation in research models. Canadian pituitary biology researchers use sermorelin as a physiologically close GHRH mimetic for stimulation testing and somatotroph biology research.
CJC-1295: Short and Long-Acting GHRH Research
CJC-1295 without DAC has ~30 min half-life and mimics pulsatile GHRH. CJC-1295 with DAC has ~7 day half-life from albumin binding. Both are used by Canadian researchers to study how pulse pattern versus sustained GHRH receptor engagement affects somatotroph output, GH pulse amplitude, and IGF-1 production.
Tesamorelin: Stable Long-Acting GHRH
Tesamorelin’s N-terminal fatty acid modification extends half-life to 26 minutes in vivo (substantially longer than sermorelin) while maintaining full GHRH receptor binding. Canadian metabolic researchers study tesamorelin for visceral fat regulation via GH stimulation in research models.
Sourcing GHRH Analogues in Canada
Research-grade sermorelin, CJC-1295, and tesamorelin are available from EhBuddy Peptides in Canada. For laboratory research use only.
